Thus, we concluded that FosB was augmented in AML and more prominent in AML-RR vs. AML-CR patients and deduced that FosB might play an important role in modulating drug sensitivity and could be a potential therapeutic target. This evidence concerns the gene FOSB and acute myeloid leukemia.